1. The median overall survival was 10.8 months in the combination group (FTD–TPI + bevacizumab) and 7.5 months in the FTD–TPI alone group, with HR 0.61. 2. The most common adverse events in both groups included neutropenia, nausea, and anemia. Evidence Rating Level: 1 (Excellent) Study Rundown: Trifluridine-tipiracil (cytotoxic nucleic acid analogue) is commonly used
The FDA has accepted for priority review the supplemental new drug application seeking the approval of trifluridine/tipiracil as a single agent or in combination with bevacizumab for use in select patients with refractory, metastatic colorectal cancer.
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.